Our Next Pathology Oncology Digital Series:

November 26, 2026

Our Next Pathology
Oncology Digital Series:

September 28, 2026

REGISTER FOR THE NEXT CAMP PODS CLICK HERE

WELCOME

CAMP PODS is a webinar series, consisting of nine one-hour sessions that will take place from January to November 2026 for an hour once a month.

The goal of this series is to build a strong Oncology Laboratory Medicine community, where best practices and common challenges can be discussed.  Insights gained will be key to implement across Canada and will help streamline laboratory workflows and practice for laboratory medicine, the end result of which will be improvements in the patient journey.

Overall Learning Objectives:

By the end of the webinar series, an audience member will:

  1. Establish a strong Oncology Education Network
  2. Compare ideas, thoughts and common challenges
  3. Identify gaps and find team solutions for improving patient care
  4. Integrate pathology and oncology practices

NEXT CAMP PODS SESSION

Thursday, November 26, 2026
9:00am – 9:50 am PT Her2 mutations in NSCLC: from biology to reporting and clinical relevance Dr. Normand Blais
Professor, Medicine at Université de Montréal
Head, Thoracic Oncology Program at the CHUM Cancer Centre
Montréal, QC
9:50am  – 10:00am PT Questions & Answers
Learning objectives:
By the end of this presentation, participants will be able to:

  1. Recognize key histopathologic features of melanocytic lesions and identify morphologic patterns that warrant further molecular investigation.

    2. Integrate histopathologic, immunohistochemical, and molecular findings to improve diagnostic accuracy in challenging melanocytic lesions.

    3. Apply molecular testing strategically in diagnostically ambiguous cases, recognizing its utility, limitations, and potential pitfalls in distinguishing benign from malignant melanocytic proliferations.

OUR LAST CAMP PODS SESSION

Thursday, October 29, 2026
9:00am – 9:50 am PT Melanocytic Lesions: Integrating Morphology and Molecular Findings (Case Based) Aleodor (Doru) Andea, MD, MBA
Professor of Oncology
Chief of Dermatopathology
Director of Molecular Dermatopathology
Department of Pathology
Roswell Park Comprehensive Cancer Center
Buffalo, NY
9:50am  – 10:00am PT Questions & Answers
Learning objectives:
By the end of this presentation, participants will be able to:

  1. Recognize key histopathologic features of melanocytic lesions and identify morphologic patterns that warrant further molecular investigation.

    2. Integrate histopathologic, immunohistochemical, and molecular findings to improve diagnostic accuracy in challenging melanocytic lesions.

    3. Apply molecular testing strategically in diagnostically ambiguous cases, recognizing its utility, limitations, and potential pitfalls in distinguishing benign from malignant melanocytic proliferations.